Cargando…

Steroidal and non-steroidal mineralocorticoid receptor antagonists in cardiorenal medicine

This review covers the last 80 years of remarkable progress in the development of mineralocorticoid receptor (MR) antagonists (MRAs) from synthesis of the first mineralocorticoid to trials of nonsteroidal MRAs. The MR is a nuclear receptor expressed in many tissues/cell types including the kidney, h...

Descripción completa

Detalles Bibliográficos
Autores principales:	Agarwal, Rajiv, Kolkhof, Peter, Bakris, George, Bauersachs, Johann, Haller, Hermann, Wada, Takashi, Zannad, Faiez
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2020
Materias:	State of the Art Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7813624/ https://www.ncbi.nlm.nih.gov/pubmed/33099609 http://dx.doi.org/10.1093/eurheartj/ehaa736

Ejemplares similares

Gonadal steroids, brain, and behavior: role of context
por: Rubinow, David R., et al.
Publicado: (2002)

Class-specific responses of brown adipose tissue to steroidal and nonsteroidal mineralocorticoid receptor antagonists
por: Marzolla, V., et al.
Publicado: (2021)

Suppression of Rapidly Progressive Mouse Glomerulonephritis with the Non-Steroidal Mineralocorticoid Receptor Antagonist BR-4628
por: Ma, Frank Y., et al.
Publicado: (2015)

Safety and tolerability of the novel non-steroidal mineralocorticoid receptor antagonist BAY 94-8862 in patients with chronic heart failure and mild or moderate chronic kidney disease: a randomized, double-blind trial
por: Pitt, Bertram, et al.
Publicado: (2013)

Nonsteroidal Mineralocorticoid Receptor Antagonist (Finerenone) in Cardiorenal Disease
por: Shah, Monarch, et al.
Publicado: (2023)

Critical Reanalysis of the Mechanisms Underlying the Cardiorenal Benefits of SGLT2 Inhibitors and Reaffirmation of the Nutrient Deprivation Signaling/Autophagy Hypothesis
por: Packer, Milton
Publicado: (2022)

Benefits of the Non-Steroidal Mineralocorticoid Receptor Antagonist Finerenone in Metabolic Syndrome-Related Heart Failure with Preserved Ejection Fraction
por: Lima-Posada, Ixchel, et al.
Publicado: (2023)

30 YEARS OF THE MINERALOCORTICOID RECEPTOR: Mineralocorticoid receptor antagonists: 60 years of research and development
por: Kolkhof, Peter, et al.
Publicado: (2017)

Pathophysiology of Cardiorenal Syndrome and Use of Diuretics and Ultrafiltration as Volume Control
por: Lim, Sung Yoon, et al.
Publicado: (2021)

Finerenone, a Non-Steroidal Mineralocorticoid Receptor Antagonist, Reduces Vascular Injury and Increases Regulatory T-Cells: Studies in Rodents with Diabetic and Neovascular Retinopathy
por: Jerome, Jack R., et al.
Publicado: (2023)

Potential Impact of Non-Steroidal Mineralocorticoid Receptor Antagonists in Cardiovascular Disease
por: Rahman, Asadur, et al.
Publicado: (2023)

The novel mineralocorticoid receptor antagonist finerenone attenuates neointima formation after vascular injury
por: Dutzmann, Jochen, et al.
Publicado: (2017)

Mineralocorticoid Receptor Antagonist Treatment for Steroid-Induced Central Serous Chorioretinopathy Patients with Continuous Systemic Steroid Treatment
por: Kim, Jin Young, et al.
Publicado: (2018)

Nonsteroidal Mineralocorticoid Receptor Antagonism by Finerenone—Translational Aspects and Clinical Perspectives across Multiple Organ Systems
por: Kolkhof, Peter, et al.
Publicado: (2022)

Real-world evidence for steroidal mineralocorticoid receptor antagonists in patients with chronic kidney disease
por: Folkerts, Kerstin, et al.
Publicado: (2022)

The non-steroidal mineralocorticoid receptor antagonist finerenone and heart failure with preserved ejection fraction
por: Kintscher, Ulrich, et al.
Publicado: (2023)

Left ventricular remodelling post-myocardial infarction: pathophysiology, imaging, and novel therapies
por: Frantz, Stefan, et al.
Publicado: (2022)

Glucagon-like peptide-1 receptor agonists in diabetic kidney disease: A review of their kidney and heart protection
por: Michos, Erin D., et al.
Publicado: (2023)

SAT-LB106 Metabolic and Brown Adipose Tissue-Specific Effects of the Novel Non-Steroidal Mineralocorticoid Receptor Antagonist Finerenone in a Mouse Model of Diet-Induced Obesity
por: Marzolla, Vincenzo, et al.
Publicado: (2020)

The intersection of pharmacology, imaging, and genetics in the development of personalized medicine
por: Gerretsen, Philip, et al.
Publicado: (2009)

Neuropsychiatric genomics in precision medicine: diagnostics, gene discovery, and translation
por: Need, Anna C., et al.
Publicado: (2016)

Artificial Intelligence in Nuclear Medicine: Opportunities, Challenges, and Responsibilities Toward a Trustworthy Ecosystem
por: Saboury, Babak, et al.
Publicado: (2023)

Finerenone: Questions and Answers—The Four Fundamental Arguments on the New-Born Promising Non-Steroidal Mineralocorticoid Receptor Antagonist
por: Di Lullo, Luca, et al.
Publicado: (2023)

Adaptive Biomedical Innovation: Evolving Our Global System to Sustainably and Safely Bring New Medicines to Patients in Need
por: Hirsch, G, et al.
Publicado: (2016)

Structural analysis of the evolution of steroid specificity in the mineralocorticoid and glucocorticoid receptors
por: Baker, Michael E, et al.
Publicado: (2007)

Mineralocorticoid Receptor Antagonists, Blood Pressure, and Outcomes in Heart Failure With Reduced Ejection Fraction
por: Serenelli, Matteo, et al.
Publicado: (2020)

Modifying chronic kidney disease progression with the mineralocorticoid receptor antagonist finerenone in patients with type 2 diabetes
por: DeFronzo, Ralph A., et al.
Publicado: (2022)

Nonsteroidal Mineralocorticoid Receptor Antagonist Eliciting Cardiorenal Protection Is a New Option for Patients with Chronic Kidney Disease
por: Liu, Wenyu, et al.
Publicado: (2022)

Individual differences in the neuropsychopathology of addiction
por: George, Olivier, et al.
Publicado: (2017)

The Non-Steroidal Mineralocorticoid Receptor Antagonist KBP-5074 Limits Albuminuria and has Improved Therapeutic Index Compared With Eplerenone in a Rat Model With Mineralocorticoid-Induced Renal Injury
por: Jaisser, Frédéric, et al.
Publicado: (2021)

Efficacy and Safety of Novel Non-steroidal Mineralocorticoid Receptor Antagonist Finerenone in the Management of Diabetic Kidney Disease: A Meta-analysis
por: Dutta, Deep, et al.
Publicado: (2022)

Cardiovascular Complications of Down Syndrome: Scoping Review and Expert Consensus
por: Dimopoulos, Konstantinos, et al.
Publicado: (2023)

Exercise-Induced Cardiac Troponin Elevations: From Underlying Mechanisms to Clinical Relevance
por: Aengevaeren, Vincent L., et al.
Publicado: (2021)

Pharmacological Approaches to Limit Ischemic and Reperfusion Injuries of the Heart: Analysis of Experimental and Clinical Data on P2Y(12) Receptor Antagonists
por: Maslov, Leonid N., et al.
Publicado: (2022)

Demystifying “Steroid Withdrawal” During Remission in Cushing's Disease: Is Mineralocorticoid Replacement the Answer?
por: Jain, Nimisha, et al.
Publicado: (2019)

New Perspectives on Sex Steroid and Mineralocorticoid Receptor Signaling in Cardiac Ischemic Injury
por: Bienvenu, Laura A., et al.
Publicado: (2022)

PF-03882845, a non-steroidal mineralocorticoid receptor antagonist, prevents renal injury with reduced risk of hyperkalemia in an animal model of nephropathy
por: Orena, Stephen, et al.
Publicado: (2013)

Mineralocorticoid receptor antagonists: emerging roles in cardiovascular medicine
por: Funder, John W
Publicado: (2013)

Cardiovascular Precision Medicine in the Genomics Era
por: Dainis, Alexandra M., et al.
Publicado: (2018)

Contemporary role of medical genetics in internal medicine
por: Saracyn, Marek, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_h876vvkq7o3v6e6603732kehjp